The role of EGFR in KRASG12D-driven tumorigenesis was studied using mouse CRC organoids with KRAS-APC-TP53 mutations and ...

Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF ...

It was a randomised, open-label, non-comparative, multicentre, phase II study which enrolled treatment naïve patients with EGFR-mutant (exon 19 deletion and L858R mutation only) metastatic NSCLC.

In the recent study, Ramalingam found that people with Stage III lung cancer who had EGFR mutations had an 84% lower risk of ...

Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR ...